Citadel Advisors
QTTB icon

Citadel Advisors’s Q32 Bio QTTB Stock Holding History

Citadel Advisors’s Portfolio QTTB Stock Details QTTB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$99.4K Sell
15,481
-30,247
-66% -$144K ﹤0.01% 12029
2025
Q4 		$152K Buy
45,728
+35,611
+352% +$101K ﹤0.01% 11308
2025
Q3 		$20K Buy
+10,117
New +$19.4K ﹤0.01% 12489
2024
Q3 		– Sell
-18,119
Closed -$325K – 15424
2024
Q2 		$325K Buy
18,119
+8,058
+80% +$193K ﹤0.01% 8975
2024
Q1 		$171K Buy
10,061
+6,217
+162% +$85.7K ﹤0.01% 10563
2023
Q4 		$42.1K Sell
3,844
-44,996
-92% -$658K ﹤0.01% 11969
2023
Q3 		$1.03M Buy
48,840
+8,779
+22% +$179K ﹤0.01% 6499
2023
Q2 		$638K Sell
40,061
-10,169
-20% -$183K ﹤0.01% 7404
2023
Q1 		$931K Sell
50,230
-11,523
-19% -$287K ﹤0.01% 6935
2022
Q4 		$1.4M Buy
61,753
+1,359
+2% +$36.1K ﹤0.01% 6174
2022
Q3 		$1.75M Buy
60,394
+2,038
+3% +$83.1K ﹤0.01% 5839
2022
Q2 		$2.07M Buy
58,356
+34,147
+141% +$1.17M ﹤0.01% 5478
2022
Q1 		$1.32M Buy
24,209
+12,588
+108% +$782K ﹤0.01% 7043
2021
Q4 		$762K Buy
11,621
+9,783
+532% +$950K ﹤0.01% 8611
2021
Q3 		$260K Buy
1,838
+270
+17% +$34.4K ﹤0.01% 11393
2021
Q2 		$205K Buy
1,568
+372
+31% +$46.4K ﹤0.01% 12109
2021
Q1 		$203K Sell
1,196
-52,916
-98% -$11.1M ﹤0.01% 11669
2020
Q4 		$11M Buy
54,112
+52,560
+3,387% +$10.2M ﹤0.01% 2514
2020
Q3 		$299K Sell
1,552
-224
-13% -$50.2K ﹤0.01% 8137
2020
Q2 		$486K Buy
1,776
+823
+86% +$219K ﹤0.01% 7129
2020
Q1 		$266K Sell
953
-346
-27% -$106K ﹤0.01% 7535
2019
Q4 		$484K Sell
1,299
-39,430
-97% -$11.3M ﹤0.01% 6853
2019
Q3 		$13.3M Buy
40,729
+38,384
+1,637% +$13M 0.01% 1904
2019
Q2 		$826K Buy
+2,345
New +$922K ﹤0.01% 6013
2018
Q3 		– Sell
-893
Closed -$328K – 9778
2018
Q2 		$328K Sell
893
-506
-36% -$181K ﹤0.01% 7066
2018
Q1 		$471K Buy
+1,399
New +$470K ﹤0.01% 5977

Other funds holding QTTB

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors's QTTB Position: Q1 2026 in Review

Citadel Advisors reduced its Q32 Bio (QTTB) stake by 66% in Q1 2026, selling an estimated $144K and leaving 15,481 shares worth $99.4K. The position accounts for ﹤0.01% of the portfolio, ranked #12029.

Citadel Advisors first reported a position in QTTB in Q1 2018 and has held it in 26 quarters since. The position peaked at $13.3M in Q3 2019. 54 funds tracked by Wall St. Rank hold QTTB as of Q1 2026.

  • Citadel Advisors held 15,481 shares of Q32 Bio worth $99.4K as of Q1 2026.
  • Citadel Advisors sold 30,247 Q32 Bio shares in Q1 2026, an estimated $144K.
  • Q32 Bio made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #12029 holding.
  • Citadel Advisors first reported a position in Q32 Bio in Q1 2018 and has held it in 26 quarters since.
  • Citadel Advisors's Q32 Bio position peaked at $13.3M in Q3 2019.
  • 54 funds tracked by Wall St. Rank held Q32 Bio as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.